Hybrid Imaging in Malignancies of the Urinary Tract, Prostate, and Testicular Cancers



The main urologic malignancies include renal, bladder, prostate, and testicular cancers. Although positron emission tomography (PET) and PET/computed tomography (CT) play an increasing role in diagnosis and staging of many primary and metastatic tumors, it has been slow to be implemented into oncologic urology. Most malignant tumors are characterized by enhanced glucose metabolism, resulting in increased 18F-FDG uptake, which can be imaged by PET. In urology, 18F-FDG is a suboptimal tracer due to its variable uptake in some urological tumors and due to its accumulation and excretion through the urinary tract, potentially masking kidney, bladder, and prostate tumors. Thus, other PET tracers are being investigated for urologic malignancies.


Positron Emission Tomography Renal Cell Carcinoma Single Photon Emission Compute Tomography Prostate Specific Antigen Positive Predictive Value 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43.CrossRefPubMedGoogle Scholar
  2. 2.
    Kopka I, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe E. Dual-phased helical CT of the kidney. Value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR Am J Roentgenol 1997;169:1573–1578.PubMedGoogle Scholar
  3. 3.
    Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluoro-thymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med 2006;31:788–789.CrossRefPubMedGoogle Scholar
  4. 4.
    Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, Sobrio F, Bouvard G, Agostini D. Efficiency of [(18)F]FDG PET in characterizing renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003;30:1236–1245.CrossRefPubMedGoogle Scholar
  5. 5.
    Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM. Clinical role of F18-fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825–830.CrossRefPubMedGoogle Scholar
  6. 6.
    Wu H, Yen R, Shen Y, Kao CH, Lin CC, Lee CC. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas – a preliminary report. J Cancer Res Clin Oncol 2002;128:503–506.CrossRefPubMedGoogle Scholar
  7. 7.
    Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: Clinicopathologic features associated with outcome. Cancer 2003;97:2425–2431.CrossRefPubMedGoogle Scholar
  8. 8.
    Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nuc Med Mol Imaging 2005;32:1412–1417.CrossRefGoogle Scholar
  9. 9.
    Kosuda S, Kison PV, Greenough, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nuc Med 1997;24:615–620.Google Scholar
  10. 10.
    Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006;36:51–72.CrossRefPubMedGoogle Scholar
  11. 11.
    DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805–1814.PubMedGoogle Scholar
  12. 12.
    Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, Shapiro A, Katz R, Libson E, Chisin R. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006;176:940–944.CrossRefPubMedGoogle Scholar
  13. 13.
    de Jong IJ, Pruim J, Slsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualization of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nuc Med Mol Imaging 2002;29:1283–1288.CrossRefGoogle Scholar
  14. 14.
    Shreve P, Chiao P-C, Humes HD, Schwaiger M, Gross MD. Carbon-11 acetate PET imaging of renal disease. J Nucl Med 1995;36:1595–1601.PubMedGoogle Scholar
  15. 15.
    Ahlstrom H, Malmstrom P-U, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiologica 1996;37:1870–1875.Google Scholar
  16. 16.
    Hankey BF, Feuer EJ, Clegg LX, Hayes GB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer – part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017–1024.CrossRefPubMedGoogle Scholar
  17. 17.
    Reske SN, Blumstein NM, Neumaier B, Gottfried H-W, Finsterbusch F, Kocot D, Möller P, Glatting G, Perner S. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249–1254.PubMedGoogle Scholar
  18. 18.
    Scher B, Seitz M, Albinger W, Tiling R,Scherr M,Becker H-C, Souvatzogluou M, Gildehaus F-J, Wester H-J, Dresel S. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642–1649.PubMedGoogle Scholar
  20. 20.
    Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954–960.CrossRefPubMedGoogle Scholar
  21. 21.
    Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tonon C, Monetti N, Castellucci P, Fanti S, Coe M, Grigioni WF, Martorana G, Canini R, Barbiroli B. Prostate cancer: Sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007;244:797–806.CrossRefPubMedGoogle Scholar
  22. 22.
    Swinnen JV, Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Mol Biol 1998;65:191–198.CrossRefPubMedGoogle Scholar
  23. 23.
    Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181–186.PubMedGoogle Scholar
  24. 24.
    Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki N. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: Comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1492–1495.CrossRefPubMedGoogle Scholar
  25. 25.
    Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, Burgers JK, Texter JH, Neal CE, Libertino JA, Wright GL Jr, Maguire RT. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology 1999;54:1058–1063.CrossRefPubMedGoogle Scholar
  26. 26.
    Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 2005;184:676–680.PubMedGoogle Scholar
  27. 27.
    Ellis RJ, Kim EY, Zhou H, et al: Seven-Year biochemical disease-free survival rates following permanent prostate brachytherapy with dose escalation to biological tumor volumes (BTVs) identifies with SPECT/CT image fusion [abstract]. Brachytherapy 2005;4:107.Google Scholar
  28. 28.
    Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46–55.PubMedGoogle Scholar
  29. 29.
    Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, Finn RD, Reddy D, Horowitz SM, Goldsmith SJ, Scher HI. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693–697.CrossRefPubMedGoogle Scholar
  30. 30.
    Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913–918.CrossRefPubMedGoogle Scholar
  31. 31.
    Fricke E, Machtens S, Hofmann M, Van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607–611.CrossRefPubMedGoogle Scholar
  32. 32.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287–297.PubMedGoogle Scholar
  33. 33.
    Scher B, Seitz M. PET/CT imaging of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:5–8.CrossRefPubMedGoogle Scholar
  34. 34.
    de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32–38.CrossRefPubMedGoogle Scholar
  35. 35.
    Cimitan M, Bortolus R, Morassut S, Canzonieri V,Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovò MG. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387–1398.CrossRefPubMedGoogle Scholar
  36. 36.
    Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549–555.PubMedGoogle Scholar
  37. 37.
    Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan H, Keller A, Bischof Delaloye A,Ratib O, Miralbell R. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007;34:185–196.CrossRefPubMedGoogle Scholar
  38. 38.
    Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006;24:2513–2519.CrossRefPubMedGoogle Scholar
  39. 39.
    Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999;53:808–811.CrossRefPubMedGoogle Scholar
  40. 40.
    Hain SF, O′Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000;27:590–594.CrossRefPubMedGoogle Scholar
  41. 41.
    Cremerius U, Wildberger JE, Borchers H, Zimny M, Jakse G, Günther RW, Buell W. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900–904.CrossRefPubMedGoogle Scholar
  42. 42.
    Huddart RA, O′Doherty MJ, Padhani A, Rustin GJS, Mead JM, Joffe JK, Vasey P, Harland SJ, Logue J, Daugaard G, Hain SF, Kirk SJ, MacKewn JE, Stenning SP. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007;25:3090–3095.CrossRefPubMedGoogle Scholar
  43. 43.
    Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975–1979.CrossRefPubMedGoogle Scholar
  44. 44.
    Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002;94:2353–2356.CrossRefPubMedGoogle Scholar
  45. 45.
    Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types Task Force. J Natl Compr Canc Netw 2009;7 Suppl 2:S1–S23. www.nccn.org/professionals/physician_gls/f_guidelines.asp Google Scholar
  46. 46.
    Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806–1809.CrossRefPubMedGoogle Scholar
  47. 47.
    Maijhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003;21:3995–4000.CrossRefGoogle Scholar
  48. 48.
    Ficarra V, Righetti R, Pilloni S, D’amico A, Maffei N, Novella G, Zanolla L, Malossini G, Mobilio G. Prognostic factors in patients with renal cell carcinoma : Retrospective analysis of 675 cases. Eur Urol 2002;41:190–198.CrossRefPubMedGoogle Scholar
  49. 49.
    Kim B, Semelka RC, Ascher S, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast- enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193:239–245.PubMedGoogle Scholar
  50. 50.
    Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick ML. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000; 163:1693–1696.CrossRefPubMedGoogle Scholar
  51. 51.
    Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lumphadenectomy necessary in the staging of prostate cancer? Br J Urol 1995;75:778–781.CrossRefPubMedGoogle Scholar
  52. 52.
    de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331–335.PubMedGoogle Scholar
  53. 53.
    Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9–17.CrossRefPubMedGoogle Scholar
  54. 54.
    Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18–23.CrossRefPubMedGoogle Scholar
  55. 55.
    Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S, Franzius C, Kliesch S, Heicappel R, Miller K. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 2008;179:936–940.CrossRefPubMedGoogle Scholar
  56. 56.
    De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034–1039.CrossRefPubMedGoogle Scholar
  57. 57.
    Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457–3460.PubMedGoogle Scholar
  58. 58.
    Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part II. Eur Urol 2008 53:497–513.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Biophysics and Nuclear MedicineHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Department of Biophysics and Nuclear MedicineHadassah Medical CenterJerusalemIsrael

Personalised recommendations